Premium
Retrospective study of metachronous lung metastases from primary hepatocellular carcinoma
Author(s) -
Chok Kenneth S. H.,
Yau Thomas C. C.,
Cheung Tan To,
Poon Ronnie T. P.,
Lo Chung Mau
Publication year - 2016
Publication title -
anz journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.426
H-Index - 70
eISSN - 1445-2197
pISSN - 1445-1433
DOI - 10.1111/ans.12859
Subject(s) - medicine , hepatocellular carcinoma , lung , gastroenterology , carcinoma , hepatectomy , overall survival , retrospective cohort study , survival rate , oncology , surgery , resection
Background This study investigates whether there has been any survival improvement for hepatocellular carcinoma patients with resectable and unresectable lung metastases over time. Methods The data of 280 hepatocellular carcinoma patients who developed metachronous lung metastases after hepatectomy with curative intent were analysed. Overall survival was compared in patients with resectable and unresectable lung metastases and in different periods ( E ra I : 1989–1995, E ra II : 1996–2010). Results The median overall survival of patients with unresectable and resectable diseases was 7.46 and 40.36 months, respectively ( P < 0.0001). In E ra I , the median overall survival of patients with unresectable and resectable diseases was 5.59 and 43.15 months, respectively ( P < 0.0001). The corresponding figures in E ra II were 8.38 and 32.90 months ( P < 0.0001). The overall survival of patients with resectable disease did not differ significantly in the two eras but there was a significant improvement in survival of patients with unresectable disease in E ra II . Their 1‐year, 3‐year and 5‐year survival rates in E ra I versus E ra II were 11.1% versus 38.4%, 5.6% versus 9.1% and 2.8% versus 3.5%, respectively ( P = 0.041). The corresponding figures for their counterparts in the resectable group were 90% versus 85.8%, 80% versus 45.9% and 40% versus 29.5%, respectively ( P = 0.443). Conclusions Patients with resectable lung metastases had better overall survival than those with unresectable lung metastases. Notably, patients with unresectable lung metastases had significant improvement in survival over the years.